This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, comparative trial of a dendritic cell vaccine loaded with Wilms’ tumor gene 1 (WT1) peptides (TLP0-001) as a potential vaccine therapy for patients with advanced pancreatic cancer refractory to standard chemotherapy. Here, WT1 is linked to familial pancreatic carcinoma.